Structural modification of an orally active thrombin inhibitor, LB30057: Replacement of the D-pocket-binding naphthyl moiety

Bioorganic and Medicinal Chemistry

Volumn 6, Issue 6, 1998, Pages 869-876

  Lee, Koo ^a   Hwang, Sang Yeul ^a   Hong, Seongwon ^a   Hong, Chang Yong ^a   Lee, Chang Seok ^a   Shin, Youseung ^a   Kim, Sangsoo ^a   Yun, Mikyung ^a   Yoo, Yung Joon ^a   Kang, Myunggyun ^a   Oh, Yeong Soo ^a  

^a LG Chemical Ltd   (South Korea)

Author keywords

Amidrazone; Inhibitor; Oral; Selective; Thrombin

Indexed keywords

LB 30057; NAPHTHYL GROUP; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CATTLE; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; TRYPSIN INHIBITORS;

EID: 0031860564     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(98)00044-3     Document Type: Article

References (34)

1. (a) Edmunds, J. J.; Rapundalo, S. T. Ann. Rep. Med. Chem. 1996, 31, 51.
2. (b) Stone, S. R. Trends Cardiovasc. Med. 1995, 5, 134.
3. (c) Tapparelli, C.; Metternich, R.; Ehrhardty, C.; Cook, N. S. Trends Pharm. Sci. 1993, 366.
4. (a) Das, J.; Kimball, S. D. Bioorg. Med. Chem. 1995, 3, 999.
5. (b) Lyle, T. A. Perspectives in Drug Discovery and Design 1994, 1, 453.
6. (c) Kaiser, B; Hauptmann, J. Cardiovasc. Drug Revs. 1992, 10, 71.
7. For a review, see ref. 2a; for recent references, see: (a) Feng, D.-M.; Gardell, S. J.; Lewis, S. D.; Bock, M. G.; Chen, Z.; Freidinger, R. M.; Naylor-Olsen, A. M.; Ramjit, H. G.; Woltmann, R.; Baskin, E. P.; Lynch, J. J.; Lucas, R.; Shafer, J. A.; Chen, I-W.; Dancheck, K. B.; Mao, S.-S.; Krueger, J. A.; Hare, T. R; Mulichak, A. M.; Vacca, J. P. J. Med. Chem. 1997, 40, 3726.
8. (b) Tucker, T. J.; Lumma, W. C.; Lewis, S. D.; Gardel, S. J.; Lucas, B. J.; Sisko, J. T.; Lynch, J. J.; Lyle, E. A.; Baskin, E. P.; Woltmann, R. F.; Appleby, S. D.; Chen, I-W.; Dancheck, K. B.; Naylor-Olsen, A. M.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. J. Med. Chem. 1997, 40, 3687.
9. (c) Sall, D. J.; Bastian, J. A.; Briggs, S. L.; Buben, J. A.; Chirgadze, N. Y.; Clawson, D. K.; Denney, M. L.; Giera, D. D.; Gifford-Moor, D. S.; Harper, R. W.; Hauser, K. L.; Klimkowski, V. J.; Kohn, T. J.; Lin, H.-S.; McCowan, J. R.; Palkowitz, A. D.; Smith, G. F.; Takeuchi, K.; Thrasher, K. J.; Tinsley, J. M.; Utterback, B. G.; Yan, S.-C. B.; Zhang, M. J. Med. Chem. 1997, 40, 3489.
10. (d) Sturzebecher, J.; Prasa, D.; Hauptmann, J.; Vieweg, H.; Wikstrom, P. J. Med. Chem. 1997, 40, 3091.
11. (e) Tamura, S. Y.; Semple, J. E.; Reiner, J. E.; Goldman, E. A.; Brunck, T. K.; Lim-Wilby, M. S.; Carpenter, S. H.; Rote, W. E.; Oldeshulte, G. L.; Richard, B. M. Bioorg. Med. Chem. Lett. 1997, 7, 1543.
12. (f) Sanderson, P. E. J.; Dyer, D. L.; Naylor-Olsen, A. M.; Vacca, J. P.; Gardel, S. J.; Lewis, S. D.; Lucas Jr., B. J.; Lyle, E. A.; Lynch, J. J.; Mulichak, A. M. Bioorg. Med. Chem. Lett. 1997, 7, 1497.
13. (g) Tucker, T. J.; Lumma, W. C.; Lewis, S. D.; Gardel, S. J.; Lucas, B. J.; Baskin, E. P.; Woltmann, R.; Lynch Jr., J. J.; Lyle, E. A.; Appleby, S. D.; Chen, I.-W.; Dancheck, K. B.; Vacca, J. P. J. Med. Chem. 1997, 40, 1565.
14. (h) Tucker, T. J.; Lumma, W. C.; Mulichak, A. M.; Chen, Z.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, R.; Freidinger, R. M.; Kuo, L. C. J. Med. Chem. 1997, 40, 830.
15. (i) Levy, O. E.; Semple, J. E.; Lim, M. L.; Reiner, J.; Rote, W. E.; Dempsey, E.; Richard, B. M.; Zhang, E.; Tulinsky, A.; Ripka, W. C.; Nutt, R. F. J. Med. Chem. 1996, 39, 4527.
16. (j) Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ha-Uong, T.; Minami, N. K.; Owens, T. D.; Tamura, S. Y.; Goldman, E. A.; Siev, D. V.; Ardecky, R. J.; Carpenter, S. H.; Ge, Y.; Richard, B. M.; Nolan, T. G.; Hakanson, K.; Tulinsky, A.; Nutt, R. F.; Ripka, W. C. J. Med. Chem. 1996, 39, 4531.
17. (k) Costanzo, M. J.; Maryanoff, B. E.; Hecker, L. R.; Schott, M. R.; Yabut, S. C.; Zhang, H.-C.; Andrade-Gordon, P.; Kauffman J. A.; Lewis, J. M.; Krishnan, R.; Tulinsky, A. J. Med. Chem. 1996, 39, 3039.
18. Kimball, S. D. Blood Coag. Fibrinol., 1995, 6, 511.
19. Nα-(4-toluenesufonyl)-p-amidinophenylalanyl-piperidine: (a) Markwardt, F.; Wagner, G; Sturzebecher, J.; Walsmann, P. Thromb. Res. 1980, 17, 425.
20. (b) Turk, D.; Sturzebecher, J.; Bode, W. FEBS Lett. 1991, 287, 133.
21. Kim, S.; Hwang, S. Y.; Kim, Y. K.; Yun, M. K.; Oh, Y. S. Bioorg. Med. Chem. Lett. 1997, 7, 769.
22. Oh, Y. S.; Kim, S. S.; Hwang, S. Y.; Yun, M. K.; Hwang, S. R.; Hong, S. W.; Lee, Y. H.; Jeong, Y. N.; Lee, K.; Shin, Y. S. European Patent Application EP739886-A2, 1996; Chem. Abstr. 1996. 126, 47554.
23. (a) Oh, Y. S.; Yun, M.; Hwang, S. Y.; Hong, S.; Lee, K.; Lee, Y. H.; Kim, S. 214th ACS National Meeting 1997, Las Vegas, NV, Abstract MEDI 63.
24. (b) Kim, I.-C.; Oh, Y. S.; Yun, M.; Hwang, S. Y.; Hong, S.; Lee, Y. H.; Lee, K.; Kim, S.; Yoo, Y. J.; Yoon, K. H.; Kim, D. S.; Lee, C. H. 70th American Heart Association 1997, Orlando, FL, Abstract 214.
25. (a) Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tezuka, T.; Tonomura, S.; Okamoto, S.; Hijikata, A. J. Med. Chem. 1980, 23, 1293.
26. (b) Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tezuka, T.; Tonomura, S.; Okamoto, S.; Funahara, Y.; Hijikata, A. J. Med. Chem. 1980, 23, 830.
27. Very recently, biaryl moieties were utilized as P2/P3 surrogates of DuP-714 in boronate thrombin inhibitors, cf.: Quan, M. L.; Wityak, J.; Dominguez, C.; Duncia, J. V.; Kettner, C. A.; Ellis, C. D.; Liauw, A. Y.; Park, J. M.; Santella, J. B.; Knabb, R. M.; Thoolen, M. J.; Webber, P. C.; Wexler, R. R. Bioorg. Med. Chem. Lett. 1997, 7, 1595.
28. The anthracene moiety has been used by the Roche group in both benzamidine- and benzamidrazone-based thrombin inhibitors, cf.: Banner, D. W.; Ackermann, J.; Gast, A.; Gubernator, K.; Hadvary, P.; Hilpert, K.; Labler, L.; Müller, K.; Schmid, G.; Tschopp, T. B.; van de Waterbeemd, H.; Wirz, B. In Perspectives in Medicinal Chemistry; Testa, B.; Kyburz, E.; Fuhrer, W.; Giger, R., Eds; Verlag Helvetica Chimica Acta: Basel, 1993; p 27.
29. Pharmacokinetic studies of compound 2 were previously described, and its oral bioavailability was estimated to be 15% in rats: see ref. 7.
30. Loewenthal, H. J.; Gottlieb, L. J. Org. Chem. 1992, 57, 2631.
31. This material is commercially available from Synthetech, Inc., Albany, OR, USA.
32. Giardina, G.; Clarke, G. D.; Dondio, G.; Petrone, G.; Sbacchi, M.; Vecchietti, V. J. Med. Chem. 1994, 37, 3482.
33. Ngai, P. K.; Chang, J. Biochem. J. 1991, 280, 805.
34. Dixon, M. Biochem. J. 1953, 55, 170.